PBAC's latest decision on Buprenorphine; oxycodone + naloxone: Deferred (2015). Considered for Additional strengths for management of pain (buprenorphine patches) and non-cancer pain (oxycodone + naloxone tablets).
PBAC outcome
Deferred
Not applicable
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2015
Submissions
1
2015 → 2015
Eligible population
Patients requiring buprenorphine patches at higher doses and patients requiring oxycodone + naloxone at varying strengths for pain management, including elderly patients with musculoskeletal pain and those in palliative/oncological settings.
Therapy area
Pain
Line of therapy
Any
Evidence base
Other
Economic model
Not modelled
ICER note
Minor submissions; no economic evaluation conducted.